Lots of interesting abstracts and cases were submitted for TCTAP 2026. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge!
ABS20251110_0006
Outcomes in Patients With Calcified Coronary Lesions Undergoing Percutaneous Coronary Intervention With Drug-Coated Balloons
By Christian Sunur, Prabahkar Subramaniam, Chai Yih Tan, Kai Soon Liew, Nancy Virginia, Muhammad Anis bin Abdul Aziz, Nurul Syifaa Najwa Binti Ahmad Nadzri, Muhammad Noor Azalizam Bin Abdullah, Wirash Kehasukcharoen, Anek Kanoksilp, Saravanan Krishinan, Kantha Rao Narasamuloo, Dharmaraj Karthikesan
Presenter
Christian Sunur
Authors
Christian Sunur1, Prabahkar Subramaniam1, Chai Yih Tan1, Kai Soon Liew1, Nancy Virginia1, Muhammad Anis bin Abdul Aziz1, Nurul Syifaa Najwa Binti Ahmad Nadzri1, Muhammad Noor Azalizam Bin Abdullah1, Wirash Kehasukcharoen2, Anek Kanoksilp2, Saravanan Krishinan1, Kantha Rao Narasamuloo1, Dharmaraj Karthikesan1
Affiliation
Hospital Sultanah Bahiyah, Malaysia1, Central Chest Institute of Thailand, Thailand2
View Study Report
ABS20251110_0006
Calcified Lesion
Outcomes in Patients With Calcified Coronary Lesions Undergoing Percutaneous Coronary Intervention With Drug-Coated Balloons
Christian Sunur1, Prabahkar Subramaniam1, Chai Yih Tan1, Kai Soon Liew1, Nancy Virginia1, Muhammad Anis bin Abdul Aziz1, Nurul Syifaa Najwa Binti Ahmad Nadzri1, Muhammad Noor Azalizam Bin Abdullah1, Wirash Kehasukcharoen2, Anek Kanoksilp2, Saravanan Krishinan1, Kantha Rao Narasamuloo1, Dharmaraj Karthikesan1
Hospital Sultanah Bahiyah, Malaysia1, Central Chest Institute of Thailand, Thailand2
Background
Percutaneous coronary intervention (PCI) using a drug-coated balloon (DCB)-only strategy remains investigational for the treatment of calcified coronary lesions.
Methods
This retrospective, descriptive, single-arm study included patients with calcified coronary lesions who underwent DCB-only PCI between January 2023 and May 2024 at a single center. Calcification was identified by angiography or intravascular imaging. Patients who received hybrid treatment defined as the combination of a DCB and a drug-eluting stent (DES) or were lost to follow-up were excluded. Baseline characteristics, procedural details, and clinical outcomes, including cardiovascular death, target vessel myocardial infarction (TVMI), and clinically driven target lesion revascularization (CD-TLR), were collected at 30 days and 1 year.
Results
A total of 52 patients underwent DCB-only PCI for calcified coronary lesions. After excluding three patients lost to follow-up, 49 were analyzed. Most were male (73.5%) with a median left ventricular ejection fraction of 56%. The clinical indications were chronic coronary syndrome (61.3%), and acute coronary syndrome (38.7%), with the left anterior descending artery being the most frequently involved vessel (69.8%). Chronic total occlusion and bifurcation lesions were present in 38.5% and 6.1% of cases, respectively. Intravascular imaging was used in 30.6% of patients. Calcium length > 10 mm was observed in 63.3% of lesions. No patients underwent rotational atherectomy, orbital atherectomy, or intravascular lithotripsy. All lesions were prepared using modified balloons, predominantly cutting (59.2%) and scoring (40.8%). The median DCB size and total length were 3.0 mm (range 2.5-4.0 mm) and 35 mm (range 15-90 mm). Most DCBs were paclitaxel-based (75.5%). At 30-day follow-up, one cardiovascular death (1.9%) occurred. No TVMI or CD-TLR was observed. No further events occurred at 1 year.
Conclusion
DCB-only PCI for calcified coronary lesions was associated with low observed rates of adverse clinical events at both 30-day and 1-year follow-up in this single-center cohort. These findings may help guide the design of future prospective studies.